Recently, irbesartan, an angiotensin type 1 receptor antagonist used for treating hypertension, was shown to overcome Gem resistance in PDAC models by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. This evidence concerns the gene JUN and Hypertension.